Our parent company, Atann Holdings, has successfully completed the acquisition of a previously certified pharmaceutical manufacturing facility. The design, installation and qualification of minor modifications to the building are almost complete. This has allowed Lompostran to start sourcing and qualifying all of our manufacturing and analytical equipment.
The strategic decision to purchase a previously licensed pharmaceutical facility has significantly fast tracked Lompostran’s timeline. This will enable Lompostran to offer the much-needed GMP contract manufacturing services to the Portuguese and European medicinal cannabis industries towards the end of 2021.